Find Adalimumab manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0INTERMEDIATES

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

46 RELATED EXCIPIENT COMPANIES

94EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set

Listed Suppliers

read-more
read-more

01

LGM Pharma

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content

Adalimumab

About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...

LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, analytical method development and testing, and commercial manufacturing. LGM Pharma offers custom API synthesis, analytical development, and regulatory services. With a network of over 300 accredited CGMP manufacturing partners, LGM provides unparalleled supply chain security. And, with over 100,000 square feet of FDA-inspected cGMP manufacturing and warehouse capacity, LGM Pharma provides a one-stop solution for solid dose, powder, semi-solid and liquid drugs.
LGM Pharma CB

02

arrow
BIO Partnering at JPM
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content

Adalimumab

About the Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...

​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry.
Shanghai Minbiotech CB

03

arrow
BIO Partnering at JPM
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMesochem is focused on incessant innovation along with the R&D of new APIs.

Flag China
Digital Content Digital Content

Adalimumab

About the Company : Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine c...

Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine chemicals and fundamental chemical materials. It has an efficient research and development team. Beijing Mesochem provides its customers customized development, craft optimization, contract customization and outsourcing services. The company has a well-established industrial base in Weinan, Shanxi Province. The production base features a 20,000 ㎡ plant with a production capacity of over 8,000 MT per year.
Mesochem Company Banner

04

Biotechnica DWC

Algeria
BIO Partnering at JPM
Not Confirmed
arrow

Biotechnica DWC

Algeria
arrow
BIO Partnering at JPM
Not Confirmed

Adalimumab

About the Company : BIOTECHNICA DWC LLC has carved a niche for itself in providing value added compliance, regulatory qualification, project management and GDP guidance services to pharma companies al...

BIOTECHNICA DWC LLC has carved a niche for itself in providing value added compliance, regulatory qualification, project management and GDP guidance services to pharma companies all over the world. Biotechnica is an integrated global solution provider from design to implementation of industrial projects in the areas of Pharmaceuticals,Agri-food ,Cosmetics and Nutrition. With more than 25 years of experience in the assembly of plants, particularly in the pharmaceutical sector, we accompany our customers in the various stages of their projects – E-CTD Dossieers – Raw Materiels – Equipements – Accessories – Packaging – Distribution.
blank

05

KinBio

Israel
BIO Partnering at JPM
Not Confirmed
arrow

KinBio

Israel
arrow
BIO Partnering at JPM
Not Confirmed

Adalimumab

About the Company : KinBio is a rapidly growing biopharmaceutical company based in Rehovot, Israel, with its main focus on developing needed therapies as well as offering a wide range of CDMO services...

KinBio is a rapidly growing biopharmaceutical company based in Rehovot, Israel, with its main focus on developing needed therapies as well as offering a wide range of CDMO services – from concept to product. KinBio’s main focus is to pursue opportunities in the global pharmaceutical market. Augmented by a global group of affiliated companies, Kinbio specializes in research, development, manufacturing and commercialization of biopharmaceutical products. Kinbio’s commitment to top standard quality is inherent across the entire global organization, from our FDA approved cGMP sites to our state of the art R&D laboratories.
blank

06

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Adalimumab

About the Company : Established in 1997, Nanogen Pharmaceutical Biotechnology JSC has been striving to become a world-class innovative biotechnology company in the pharmaceutical industry. We are pro...

Established in 1997, Nanogen Pharmaceutical Biotechnology JSC has been striving to become a world-class innovative biotechnology company in the pharmaceutical industry. We are proud to be the leading company in the Asia-Pacific region that successfully researched and developed Active Pharmaceutical Ingredients (APIs) and specific therapeutic products on the foundation of advanced recombinant DNA/protein technology.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1665772200,"product":"ADALIMUMAB DRUG SUBSTANCE","address":"CAMUS HOUSE, 29-B, SURAJ NAGAR EAST, CIVIL LINES,","city":"JAIPUR, RAJASTHAN.","supplier":"CAMUS PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"PSK PHARMA LTD.","customerCountry":"RUSSIA","quantity":"0.55","actualQuantity":"549.516","unit":"GMS","unitRateFc":"1683.6","totalValueFC":"906322.1","currency":"USD","unitRateINR":135712.15396821933,"date":"15-Oct-2022","totalValueINR":"74576000","totalValueInUsd":"906322.1","indian_port":"BOMBAY AIR","hs_no":"29379090","bill_no":"4838599","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"CAMUS HOUSE, 29-B, SURAJ NAGAR EAST, CIVIL LINES,, JAIPUR, RAJASTHAN.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1676313000,"product":"ADALIMUMAB (ADALIMUMAB) 1G","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"PSK PHARMA LTD.","customerCountry":"RUSSIA","quantity":"0.40","actualQuantity":"404.307","unit":"GMS","unitRateFc":"134948","totalValueFC":"660612.5","currency":"INR","unitRateINR":134946.95862302656,"date":"14-Feb-2023","totalValueINR":"54560000","totalValueInUsd":"660612.5","indian_port":"AHMEDABAD AIR","hs_no":"29379090","bill_no":"7777750","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1688063400,"product":"ADALIMUMAB (ADALIMUMAB) 1G","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"PSK PHARMA LTD.","customerCountry":"RUSSIA","quantity":"0.58","actualQuantity":"584.315","unit":"GMS","unitRateFc":"134948","totalValueFC":"959313.4","currency":"INR","unitRateINR":134947.75894851235,"date":"30-Jun-2023","totalValueINR":"78851999.77","totalValueInUsd":"959313.4","indian_port":"AHMEDABAD AIR","hs_no":"29379090","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1708713000,"product":"ADALIMUMAB (ADALIMUMAB)","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"PSK PHARMA LTD.","customerCountry":"RUSSIA","quantity":"0.56","actualQuantity":"558.88","unit":"GMS","unitRateFc":"136053","totalValueFC":"916401.5","currency":"INR","unitRateINR":136053,"date":"24-Feb-2024","totalValueINR":"76037300.64","totalValueInUsd":"916401.5","indian_port":"Ahmedabad Air","hs_no":"29379090","bill_no":"7803477","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1719340200,"product":"ADALIMUMAB (ADALIMUMAB)","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"PSK PHARMA LTD.","customerCountry":"RUSSIA","quantity":"0.64","actualQuantity":"642.867","unit":"GMS","unitRateFc":"137146","totalValueFC":"1056148.2","currency":"INR","unitRateINR":137145.99999688895,"date":"26-Jun-2024","totalValueINR":"88166637.58","totalValueInUsd":"1056148.2","indian_port":"Ahmedabad Air","hs_no":"29379090","bill_no":"1962658","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1732732200,"product":"ADALIMUMAB (ADALIMUMAB)","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"PSK PHARMA LTD.","customerCountry":"RUSSIA","quantity":"0.67","actualQuantity":"671.058","unit":"GMS","unitRateFc":"138639","totalValueFC":"1102462.5","currency":"INR","unitRateINR":138638.99999701962,"date":"28-Nov-2024","totalValueINR":"93034810.06","totalValueInUsd":"1102462.5","indian_port":"Ahmedabad Air","hs_no":"29379090","bill_no":"5980504","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""}]
15-Oct-2022
28-Nov-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

HUMIRA® is a fully human anti-TNF-α monoclonal antibody, got additional approval for a highdose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients.


Lead Product(s): Adalimumab

Therapeutic Area: Gastroenterology Brand Name: Humira

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Eisai

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 27, 2021

Abbvie Company Banner

01

AbbVie Inc

U.S.A
arrow
Biotech Showcase
Not Confirmed

Details : HUMIRA® is a fully human anti-TNF-α monoclonal antibody, got additional approval for a highdose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients.

Brand Name : Humira

Molecule Type : Large molecule

Upfront Cash : Not Applicable

September 27, 2021

Abbvie Company Banner

Details:

HUMIRA (adalimumab) is the first and only subcutaneous biologic treatment option for pediatric patients from 5 years of age with moderately to severely active ulcerative colitis.


Lead Product(s): Adalimumab

Therapeutic Area: Gastroenterology Brand Name: Humira

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 24, 2021

Abbvie Company Banner

02

AbbVie Inc

U.S.A
arrow
Biotech Showcase
Not Confirmed

Details : HUMIRA (adalimumab) is the first and only subcutaneous biologic treatment option for pediatric patients from 5 years of age with moderately to severely active ulcerative colitis.

Brand Name : Humira

Molecule Type : Large molecule

Upfront Cash : Not Applicable

April 24, 2021

Abbvie Company Banner

Details:

Approval for adalimumab based on results from the pivotal Phase 3 ENVISION I study showing the higher dosage of HUMIRA induced clinical remission in 60 percent of patients at Week 8 and 45 percent of patients, who responded at Week 8, were in remission at Week 52.


Lead Product(s): Adalimumab

Therapeutic Area: Gastroenterology Brand Name: Humira

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 24, 2021

Abbvie Company Banner

03

AbbVie Inc

U.S.A
arrow
Biotech Showcase
Not Confirmed

Details : Approval for adalimumab based on results from the pivotal Phase 3 ENVISION I study showing the higher dosage of HUMIRA induced clinical remission in 60 percent of patients at Week 8 and 45 percent of patients, who responded at Week 8, were in remission a...

Brand Name : Humira

Molecule Type : Large molecule

Upfront Cash : Not Applicable

February 24, 2021

Abbvie Company Banner

Details:

Through the divestment, Coherus reinforces its strategic focus on oncology Yusimry (adalimumab) biosimilar to Humira. It is indicated for the treatment of Rheumatoid Arthritis.


Lead Product(s): Adalimumab

Therapeutic Area: Immunology Brand Name: Yusimry

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Hong Kong King-Friend Industrial Co. Ltd

Deal Size: $40.0 million Upfront Cash: $40.0 million

Deal Type: Divestment June 27, 2024

blank

04

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Lead Product(s) : Adalimumab

Therapeutic Area : Immunology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Hong Kong King-Friend Industrial Co. Ltd

Deal Size : $40.0 million

Deal Type : Divestment

Details : Through the divestment, Coherus reinforces its strategic focus on oncology Yusimry (adalimumab) biosimilar to Humira. It is indicated for the treatment of Rheumatoid Arthritis.

Brand Name : Yusimry

Molecule Type : Large molecule

Upfront Cash : $40.0 million

June 27, 2024

blank

Details:

Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent, continuing the commercialization of Boehringer Ingelheim-labeled Cyltezo.


Lead Product(s): Adalimumab

Therapeutic Area: Immunology Brand Name: Cyltezo

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Quallent Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 13, 2024

blank

05

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent, continuing the commercialization of Boehringer Ingelheim-labeled Cyltezo.

Brand Name : Cyltezo

Molecule Type : Large molecule

Upfront Cash : Undisclosed

May 13, 2024

blank

Details:

Cyltezo (adalimumab-biosimilar) is a TNF blocker indicated for rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis treatment.


Lead Product(s): Adalimumab

Therapeutic Area: Dermatology Brand Name: Cyltezo

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 01, 2024

blank

06

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Cyltezo (adalimumab-biosimilar) is a TNF blocker indicated for rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis treatment.

Brand Name : Cyltezo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

May 01, 2024

blank

Details:

Alvotech will manufacture its high-concentration interchangeable biosimilar, AVT02, a monoclonal antibody and that has been approved as a biosimilar to Humira (adalimumab) for Quallent.


Lead Product(s): Adalimumab

Therapeutic Area: Immunology Brand Name: AVT02

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Alvotech

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 30, 2024

blank

07

Quallent Pharmaceuticals

Cayman Islands
arrow
Biotech Showcase
Not Confirmed

Quallent Pharmaceuticals

Cayman Islands
arrow
Biotech Showcase
Not Confirmed

Details : Alvotech will manufacture its high-concentration interchangeable biosimilar, AVT02, a monoclonal antibody and that has been approved as a biosimilar to Humira (adalimumab) for Quallent.

Brand Name : AVT02

Molecule Type : Large molecule

Upfront Cash : Undisclosed

April 30, 2024

blank

Details:

The agreement aims to further enhance access to Simlandi (adalimumab-ryvk) in the U.S. market, the newly U.S. FDA approved high-concentration interchangeable biosimilar to Humira.


Lead Product(s): Adalimumab

Therapeutic Area: Immunology Brand Name: Simlandi

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 19, 2024

blank

08

Alvotech

Iceland
arrow
Biotech Showcase
Not Confirmed

Alvotech

Iceland
arrow
Biotech Showcase
Not Confirmed

Details : The agreement aims to further enhance access to Simlandi (adalimumab-ryvk) in the U.S. market, the newly U.S. FDA approved high-concentration interchangeable biosimilar to Humira.

Brand Name : Simlandi

Molecule Type : Large molecule

Upfront Cash : Undisclosed

April 19, 2024

blank

Details:

Simlandi (adalimumab) is the first interchangeable biosimilar to Humira for various arthritic conditions and Crohn’s disease.


Lead Product(s): Adalimumab

Therapeutic Area: Immunology Brand Name: Simlandi

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Teva Pharmaceutical Industries

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 23, 2024

blank

09

Alvotech

Iceland
arrow
Biotech Showcase
Not Confirmed

Alvotech

Iceland
arrow
Biotech Showcase
Not Confirmed

Details : Simlandi (adalimumab) is the first interchangeable biosimilar to Humira for various arthritic conditions and Crohn’s disease.

Brand Name : Simlandi

Molecule Type : Large molecule

Upfront Cash : Not Applicable

February 23, 2024

blank

Details:

Hyrimoz (adalimumab-adaz) binds with specificity to TNF-alpha and inhibits its interaction with the p55 and p75 cell surface TNF receptors, which is approved for rheumatic diseases, Crohn's disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa.


Lead Product(s): Adalimumab

Therapeutic Area: Immunology Brand Name: Hyrimoz

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 21, 2023

blank

10

Sandoz B2B

Switzerland
arrow
Biotech Showcase
Not Confirmed

Sandoz B2B

Switzerland
arrow
Biotech Showcase
Not Confirmed

Details : Hyrimoz (adalimumab-adaz) binds with specificity to TNF-alpha and inhibits its interaction with the p55 and p75 cell surface TNF receptors, which is approved for rheumatic diseases, Crohn's disease, ulcerative colitis, plaque psoriasis, uveitis and hidra...

Brand Name : Hyrimoz

Molecule Type : Large molecule

Upfront Cash : Not Applicable

November 21, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Parenteral

read-more
read-more

Solubilizers

read-more
read-more

Direct Compression

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Taste Masking

read-more
read-more

Co-Processed Excipients

read-more
read-more

Granulation

read-more
read-more

Topical

read-more
read-more

Emulsifying Agents

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

API Stability Enhancers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Rheology Modifiers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty